Tag: favipiravir
FDC Limited launches Favenza – oral suspension of Covid drug Favipiravir
FDC Limited has launched Favenza Oral Suspension - an oral suspension of Favipiravir, in India for the treatment of mild to moderate cases of Covid-19. ... Read More
Glenmark reports positive interim data from PMS study on Favipiravir
Glenmark Pharmaceuticals said that interim data from its post marketing surveillance (PMS) study on Favipiravir (FabiFlu) in India supports the Covid-19 drug’s safety and effectiveness ... Read More
Bal Pharma launches BALflu – generic of Covid-19 drug Favipiravir in India
Bal Pharma Ltd has launched its generic of the Covid-19 drug Favipiravir under the brand name BALflu in India. Favipiravir has been used as an ... Read More
Bharat Parenterals gets license and authorization for Favipiravir oral suspension for Covid treatment
Bharat Parenterals said that it has secured the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO) ... Read More
Vivimed Labs launches Covid-19 drug Favulous in India
Vivimed Labs has launched Favulous, its generic version of Covid-19 drug Favipiravir Tablet 200 mg and 400 mg in India. The launch follows the approval ... Read More
Bajaj Healthcare launches Favijaj tablets for Covid-19 treatment in India
Bajaj Healthcare Limited (BHL) has launched Favijaj tablets, its generic version of Japan-based Fujifilm's antiviral drug favipiravir for the treatment of mild to moderate Covid-19 ... Read More
PRESECO clinical trial for Avigan : Appili begins dosing in phase 3 Covid-19 study
Appili Therapeutics said that it has dosed the first participant in the phase 3 PRESECO clinical trial for Avigan tablets (favipiravir) for the oral treatment ... Read More
Glenmark Pharmaceuticals launches FabiFlu for COVID-19 treatment in India
Glenmark Pharmaceuticals has secured approval from India to launch Japan-based Fujifilm's antiviral drug favipiravir under the brand name FabiFlu for the treatment of COVID-19 in ... Read More